test

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer

Conditions

Lung

Trial Phase

Phase IB

Trial Purpose and Description

Trial Purpose

The purpose of this study is to determine if ;MEDI4736 ;will be adequately tolerated in combination with tremelimumab in subjects with advanced NSCLC.


Participation Guidelines

Age:
Gender:
Both

Eligibility Criteria

Criteria

Age &ge 18 years, Advanced non-small cell lung cancer, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 Adequate organ and marrow function

Exclusion Criteria:

Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment Current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs Active or prior documented autoimmune disease within the last 3 years.

Sponsor:
MedImmune, Inc
Dates:
01/06/2014
Last Updated:
Study HIC#:
1310012856